Tosedostat

DRUG5 trials

Sponsors

Chroma Therapeutics, Fred Hutchinson Cancer Center, M.D. Anderson Cancer Center, Washington University School of Medicine, Weill Medical College of Cornell University

Conditions

AMLAcute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage DysplasiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Cancer of PancreasCancer of the Pancreas

Phase 1

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

TerminatedNCT01636609

M.D. Anderson Cancer CenterAcute Myeloid Leukemia, High Risk Myelodysplastic Syndrome

Start: 2012-11-20End: 2019-07-04Updated: 2020-04-13

Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

TerminatedNCT02352831

Washington University School of MedicineCancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer +1

Start: 2015-08-31End: 2018-10-19Updated: 2019-08-28

Phase 2

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

CompletedNCT00780598

Chroma TherapeuticsAcute Myeloid Leukemia, AML

Start: 2009-10-31End: 2011-03-31Updated: 2012-06-28

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

CompletedNCT01567059

Fred Hutchinson Cancer CenterAcute Myeloid Leukemia With Multilineage Dysplasia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) +6

Start: 2012-05-31End: 2013-06-30Updated: 2017-02-15

Study of Clinical Efficacy and Safety of Tosedostat in MDS

CompletedNCT02452346

Weill Medical College of Cornell UniversityMyelodysplastic Syndrome

Start: 2015-03-20End: 2017-10-25Updated: 2018-06-12

Related Papers

A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2017-02-018 citations

A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma.

Journal of Clinical Oncology2016-02-01

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

2013-02-2838 citations